LaymanSNGuidryTJGillionAR. Low-dose alteplase for the treatment of submassive pulmonary embolism: a case series [published online ahead of print. June 19, 2019]. J Pharm Pract. doi:10.1177/0897190019855164
2.
MeyerGVicautEDanaysT, et al.Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–1411.
3.
RothschildDPGoldsteinJABowersTR. Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: clinical efficacy but attendant hemorrhage risks. Catheter Cardiovasc Interv. 2019;93(3):506–510.
4.
KearonCAklEAOrnelasJ, et al.Antithrombotic therapy for VTE disease. Chest. 2016;149(2):315–352.
5.
JaffMRMcMurtrySArcherSL, et al.Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension a scientific statement from the American heart association. Circulation. 2011;123(16):1788–1830.
6.
BecattiniCCohenATAgnelliG, et al.Risk stratification of patients with acute symptomatic pulmonary embolism based on presence or absence of lower extremity DVT: systemic review and meta-analysis. Chest. 2016;149(1):192–200.
7.
KonstantinidesSCVicautEDanaysT, et al.Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol. 2017;69(12):1536–1544.
8.
MartiCJohnCKonstanatinidesS, et al.Systemic thrombolysis therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36(10):605–614.
